Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

News | Coronavirus (COVID-19) | June 30, 2020
June 30, 2020 — A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells...
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
News | Heart Failure | June 30, 2020
June 30, 2020 —  BioCardia, Inc. announced that the company has resumed cases in the CardiAMP Heart Failure Trial. The...
First ICM device with remote programming paired with dual-stage arrhythmia detection algorithm
News | Implantable Cardiac Monitor (ICM) | June 29, 2020
June 29, 2020 — Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx ...
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Cardiac Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic resonance imaging (MRI) scan used in people with heart disease could help...
Abbott OCT intravascular imaging explained.
News | Optical Coherence Tomography (OCT) | June 26, 2020
June 26, 2020 — Abbott announced new data from the company's LightLab Initiative that showed optical coherence...
The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients. RDN

The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients.

News | Renal Denervation | June 26, 2020
June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the...
The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventing several aspects of the prosthetic heart valve,...
Bystanders using a Philips HeartStart AED for a patient in sudden cardiac arrest.

Bystanders using a Philips HeartStart AED for a patient in sudden cardiac arrest.

News | Defibrillator Monitors | June 23, 2020
June 23, 2020 — Philips announced the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for...
Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient to treat heart failure..

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient.

News | Heart Failure | June 23, 2020
June 23, 2020 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Program status for the...
Signs for "Heroes work here" outside healthcare facilities and even the homes of clinicians have popped up across the country. This photo shows healthcare workers at the Lenox Health emergency room entrance being greeted to cheers and thanks for their essential service during the COVID-19 pandemic in New York City at a public thank you event May 21, 2020. #COVID19 #SARScov2 #pandemic #LenoxHill 

Signs for "Heroes work here" outside healthcare facilities and even the homes of clinicians have popped up across the country. This photo shows healthcare workers at the Lenox Hill emergency room entrance being greeted to cheers and thanks for their essential service during the COVID-19 pandemic in New York City at a public thank you event May 21, 2020.

Blog | Coronavirus (COVID-19) | June 22, 2020
Prior to January 2020 when clinicians read about the history of the 1918 flu, and epidemiologists predicted we were...
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt. Ltd) said it acquired of the structural heart medical device...
iVascular Launches Essential Pro Coronary Drug-coated Balloon
News | Drug-Eluting Balloons | June 19, 2020
June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon...
MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal coronary angioplasty (PTCA) sirolimus drug-eluting balloon (DEB) for the treatment of coronary artery disease. This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad range of balloon sizes, from 1.5 x 10 mm, up to 5 x 40 mm.
News | Drug-Eluting Balloons | June 18, 2020
June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal...
he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD) | June 16, 2020
June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent...
Biotronik Launchs His-Bundle Pacing Tools
News | Pacemakers | June 16, 2020
June 16, 2020 - Biotronik has today announced its commitment to giving physicians additional tools to pace in the His-...